医学
血管内超声
传统PCI
经皮冠状动脉介入治疗
狼牙棒
临床终点
心脏病学
内科学
血运重建
心肌梗塞
随机对照试验
作者
Francesco Bruno,Ovidio DE FILIPPO,Andrea Sardone,Piera Capranzano,Federico Conrotto,Imad Sheiban,Federico Giacobbe,Claudio Laudani,Francesco Burzotta,Francesco Saia,Javier Escaned,Sergio Raposeiras‐Roubín,Massimo Mancone,Christian Templin,Alessandro Candreva,Daniela Trabattoni,Wojciech Wańha,Giulio Giuseppe Stefanini,Alaide Chieffo,Bernardo Cortese
标识
DOI:10.1016/j.ijcard.2024.131861
摘要
Abstract
Introduction
The potential benefit on long term outcomes of Percutaneous Coronary Intervention (PCI) on Unprotected Left Main (ULM) driven by IntraVascular UltraSound (IVUS) remains to be defined. Methods
IMPACTUS LM-PCI is an observational, multicenter study that enrolled consecutive patients with ULM disease undergoing coronary angioplasty in 13 European high-volume centers from January 2002 to December 2015. Major Adverse Cardiovascular Events (MACEs) a composite of cardiovascular (CV) death, target vessel revascularization (TVR) and myocardial infarction (MI) were the primary endpoints, while its single components along with all cause death the secondary ones. Results
627 patients with ULM disease were enrolled, 213 patients (34%) underwent IVUS-guided PCI while 414 (66%) angioguided PCI. Patients in the two cohorts had similar prevalence of risk factors except for active smoking and clinical presentation. During a median follow-up of 7.5 years, 47 (22%) patients in the IVUS group and 211 (51%) in the angio-guided group underwent the primary endpoint (HR 0.42; 95% CI [0.31–0.58] p < 0.001). After multivariate adjustment, IVUS was significantly associated with a reduced incidence of the primary endpoint (adj HR 0.39; 95% CI [0.23–0.64], p < 0.001), mainly driven by a reduction of TVR (ad HR 0.30, 95% CI [0.15–0.62], p = 0.001) and of all-cause death (adj HR 0.47, 95% CI [0.28–0.82], p = 0.008). IVUS use, age, diabetes, side branch stenosis, DES and creatinine at admission were independent predictors of MACE. Conclusions
In patients undergoing ULM PCI, the use of IVUS was associated with a reduced risk at long-term follow-up of MACE, all-cause death and subsequent revascularization.
科研通智能强力驱动
Strongly Powered by AbleSci AI